Current version snapshot

Not FDA-approved↗Safety records↗↗

Current · version 3: Emideltide↗

Related names recorded in this version: DSIP, Delta sleep-inducing peptide↗

A nine-amino-acid peptide, also called DSIP, that is not FDA-approved. FDA’s 2026 review found its human studies small and inconclusive.↗

This immutable URL preserves the current public version.
The canonical profile remains the primary reading view. Read the canonical profile.
Update · November 14, 2026

We added a plain-language reader guide with cited answers, re-checked FDA’s emideltide briefing and compounding safety-risk page, and noted that HHS’s October 30, 2026 draft enforcement-discretion policy does not include emideltide. 146

What this version reported

FDA staff recommended in 2026 against adding emideltide or emideltide acetate to the 503A compounding list. Emideltide is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗

Organizations named in cited records:
  • U.S. Food and Drug Administration↗↗
  • U.S. Department of Health and Human Services↗

Reader guide in this version

Key takeaway

Emideltide, also called delta sleep-inducing peptide (DSIP), is a nine-amino-acid peptide first isolated from rabbits in 1977 and reported to promote sleep.1 It is not an FDA-approved drug. FDA’s 2026 evaluation found that neither emideltide nor emideltide acetate is a component of an FDA-approved drug, and FDA staff recommended against adding either to the list of substances pharmacies may use in compounding.1 FDA described its human studies, in chronic insomnia, narcolepsy and opioid withdrawal, as small and inconclusive, and found no safety data for the way the nominators proposed to use it.1 Emideltide was reviewed at FDA’s July 2026 advisory meeting but is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.2,6

At a glance

What it is
A peptide of nine amino acids, also called delta sleep-inducing peptide (DSIP), first isolated from rabbit blood and reported to have sleep-inducing properties in animals.1
FDA status
Not FDA-approved. FDA staff recommended in 2026 against adding emideltide or emideltide acetate to the 503A compounding list; FDA had not reported a final decision in the sources reviewed.1
Human evidence
Small studies, some randomized and placebo-controlled, in chronic insomnia, and uncontrolled reports in narcolepsy and opioid withdrawal. FDA found the evidence inconclusive.1
Evidence strength
Smaller controlled human trials

What is emideltide?

Emideltide is the nonproprietary name for a peptide of nine amino acids also called delta sleep-inducing peptide (DSIP). FDA’s briefing states that it was first isolated from the blood of rabbits in 1977 and shown to have sleep-inducing properties.1

It exists as a free base and as an acetate salt, which FDA treats as different substances. FDA reports evidence that emideltide-related substances have been used in compounding since at least 2018, and that they have been studied in humans since at least 1981.1

How is emideltide thought to work?

FDA’s briefing states that in animals emideltide has sleep-inducing effects that appear to work through the body’s opioid system: it does not seem to act on opioid receptors directly, but it can stimulate the release of endorphins.1

FDA notes that this action on the opioid system could lead to addiction and that it found no studies of that potential.1

What do human studies show?

FDA evaluated emideltide for chronic insomnia, narcolepsy and opioid withdrawal. For insomnia, it found small studies with mixed results: some reported better sleep, while double-blind, placebo-controlled studies of similar design did not reach the same conclusions.1

FDA describes the insomnia evidence as inconclusive and at best preliminary, citing small samples, weak or missing control groups and unclear clinical meaning.1

The narcolepsy and opioid withdrawal studies were a single case report and small studies without blinding or randomization. In withdrawal studies, headache, nausea and vertigo were common, with cases of low blood pressure, according to FDA.1

The human studies gave emideltide in a different way from the one the nominators proposed, and FDA found no safety or effectiveness data for the proposed way.1

What the evidence base contains

  • Controlled human trial A randomized, double-blind, placebo-controlled crossover study published in 1981 in six middle-aged adults with chronic insomnia, and later double-blind, placebo-controlled studies that did not reach the same conclusions.1
  • Small, short, or incompletely reported human study Small open-label studies in opioid withdrawal with no comparison group, and a single-person report in narcolepsy.1
  • Animal or laboratory research Animal studies, beginning with work in rabbits in 1977, in which emideltide-related substances changed sleep patterns.1

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is emideltide FDA-approved?

No. FDA’s evaluation, dated May 11, 2026, states that neither emideltide nor emideltide acetate is a component of an FDA-approved drug, and that there is no United States Pharmacopeia monograph for either.1

FDA staff evaluated both forms for the 503A bulks list, the list of substances that pharmacies may use in compounding. They concluded that the balance of criteria weighs against adding either, citing poor characterization, insufficient evidence of effectiveness and a lack of safety data.1

A Federal Register notice and FDA’s meeting page announced that the Pharmacy Compounding Advisory Committee would review peptides including emideltide at its July 23-24, 2026 meeting. The briefing states that FDA will not issue a final determination until the committee’s input has been considered.1,2,3

FDA’s compounding safety-risk page, current as of April 22, 2026, lists emideltide among substances whose nominations were withdrawn, noting possible immune reactions and that FDA lacks enough safety information to know whether it would cause harm.4

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Emideltide is not among them.5,6

Timeline

  1. Emideltide is first isolated from rabbit blood and reported to induce sleep, according to FDA’s briefing.1
  2. FDA’s compounding safety-risk page, as last updated, lists emideltide among withdrawn nominations with safety concerns.4
  3. FDA staff date their evaluation recommending against adding emideltide to the 503A bulks list.1
  4. FDA’s Pharmacy Compounding Advisory Committee begins its two-day meeting reviewing peptides including emideltide.2,3

What is still unknown?

Whether emideltide improves sleep or any other condition: FDA found the evidence inconclusive.1

Its safety with repeated use and in the form the nominators proposed, for which FDA found no data, and its potential for addiction.1

FDA’s final decision on the 503A list, which was not part of the sources reviewed through November 14, 2026.1,2

Sources for this version

  1. 1
    FDA briefing document for emideltide (DSIP) (free base) and emideltide acetate ↗

    U.S. Food and Drug Administration · Official source · Source checked July 29, 2026

  2. 2
    July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  3. 3
    Federal Register notice 2026-07361 · published 2026-04-16 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List ↗

    Federal Register via GovInfo · Official source · Source checked August 21, 2026

  4. 4
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  5. 5
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026